首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1682702

腫瘤精密醫療市場:標的癌症類別，各給藥途徑，各分子類型，各類藥物，主要地區，新興國家市場，預測銷售額:2035年前的產業趨勢與全球預測

Oncology Precision Medicine Market by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers and Sales Forecast: Industry Trends and Global Forecasts, Till 2035

出版日期: 2025年03月19日 | 出版商:

Roots Analysis | 英文 468 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球腫瘤精準醫療市場規模預計將從目前的 1,479 億美元增長到 2035 年的 3,640 億美元，在預測期內以 8.5% 的複合年增長率增長。

癌症被公認為最致命的疾病之一，全球約有 2000 萬新發病例和 1000 萬人死亡。根據世界衛生組織 (WHO) 的數據，到 2040 年癌症負擔預計將增加近 60%。目前，有幾種常規方法可用於治療這些致病因素，包括非傳統療法或補充療法，例如手術、放射療法、化學療法、荷爾蒙療法、免疫療法和奈米療法。然而，這些方法無法解決內在的致癌基因異常。因為這些異常對每個病人來說都是獨一無二的。為了解決這個問題，精準醫療（也稱為個人化醫療）已成為一種可能的解決方案。精準醫療的概念是考慮到腫瘤特徵、基因數據、生活方式和環境影響來提供定製藥物，它透過擺脫一刀切的治療方法，在腫瘤疾病的治療中具有巨大的潛力。鑑於技術創新的不斷步伐和對個人化醫療日益增長的偏好，預計腫瘤精準醫療市場將在未來實現顯著增長。

目前，全球有超過125家製藥開發公司正在致力於開發針對各種癌症的精準腫瘤治療，其中約90％的開發公司總部位於已開發地區。近55%的精準腫瘤藥物已商業化，其中近28%針對血癌。

臨床前和發現階段的腫瘤精準藥物中約85%是小分子化合物，其中超過30%針對激酶蛋白。過去五年來，腫瘤學領域的合作活動大幅成長，年複合成長率為 16%，擴大了精準腫瘤藥物管道。

由於癌症精準醫療具有副作用少、反應率高等優勢，預計在可預見的未來對此類藥物的偏好將穩步上升。

本報告提供全球腫瘤精密醫療市場相關調查，提供市場概要，以及標的癌症類別，各給藥途徑，各分子類型，各類藥物，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

Cancer is recognized as one of the deadliest diseases, accounting for an alarming global toll of approximately 20 million new cases and 10 million fatalities. According to the World Health Organization, the cancer burden is anticipated to rise by nearly 60 % by 2040. Currently, several conventional approaches, including surgery, radiation therapy, chemotherapy and nonconventional or complementary therapeutic methods, including hormone therapy, immunotherapy and nanotherapy are available for treating these causative variables. However, these approaches are unable to deal with intrinsic carcinogenic genetic abnormalities, owing to the fact that these irregularities are unique to each individual patient. In order to address this, precision medicine, often known as personalized medicine, emerged as a possible solution, which uses genomic knowledge to provide gene-targeted diagnostics and therapeutics. The concept of precision medicine takes into account the tumor features, genetic data, lifestyle and environmental effects to provide tailored medicines and holds significant potential in treating oncological disorders by shifting away from a one-size-fits-all approach. Given the ongoing pace of innovation, and increasing preference for personalized healthcare, the oncology precision medicine market is poised to experience a noteworthy growth in the foreseen future.

ONCOLOGY PRECISION MEDICINE MARKET: KEY INSIGHTS

The report delves into the current state of the oncology precision medicine market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently over 125 drug developers, worldwide, are engaged in developing oncology precision medicines targeting various cancers; around 90% of these developers are headquartered in developed geographies.

2. Close to 55% of the oncology precision medicines have been commercialized; of these, close to 28% of the drugs target blood / hematologic type of cancer.

3. Around 85% oncology precision medicines in the preclinical and discovery stages of development are small molecules; of these, more than 30% of the drugs target kinase proteins.

4. In pursuit of expanding the oncology precision medicines pipeline, the partnership activity in this domain has witnessed substantial growth with an annualized rate of 16% over the last five years.

5. Close to one million patients have been recruited / enrolled in clinical trials, registered for the evaluation of oncology precision medicines, across different geographies.

6. Majority of the oncology precision medicine assay kits developers are headquartered in North America; further, more than 30% of the market is captured by large players established post-1990.

7. Around 80% of oncology precision medicine assay kits are diagnostic tests; over 55% of such kits can diagnose, prognose and predict various cancers and provide results within ten days.

8. Owing to the advantages offered by precision medicines in cancer, along with lesser side effects and high response rate, the preference for such drugs will steadily increase in foreseeable future.

9. With the rapid increase in the demand for gene-targeted drugs in the treatment of cancer, the opportunity for companies developing oncology precision medicines is poised to grow at a CAGR of close to 10%.

ONCOLOGY PRECISION MEDICINE MARKET: KEY SEGMENTS

Blood / Hematologic Cancer Occupies the Largest Share of the Oncology Precision Medicine Market

Based on target cancer, the market is segmented into bladder cancer, blood / hematologic cancer, breast cancer, cervical cancer, gastrointestinal cancer, head and neck squamous cell cancer, lung cancer, skin cancer and others. At present, blood / hematologic cancer segment holds the maximum share of the oncology precision medicine market. This can be attributed to the high incidence rate of blood / hematologic cancer, accounting for approximately 1.24 million cases worldwide. It is worth highlighting that the precision oncology market for gastrointestinal cancer is likely to grow at a relatively higher CAGR.

Oral Route of Administration is the Fastest Growing Segment of the Oncology Precision Medicine Market During the Forecast Period

Based on the route of administration, the market is segmented into oral and intravenous route of administration. It is worth highlighting that in the coming years, the oral route is anticipated to grow at a relatively faster pace. This can be attributed to the various advantages offered by oral routes of administration, such as non-invasiveness, higher patient compliance and ease of administration.

Biologics Occupy the Largest Share of the Oncology Precision Medicine Market

Based on the type of molecule, the market is segmented into small molecules and biologics. At present, biologics captures the highest share of the oncology precision medicine market. However, in the coming years, small molecules are anticipated to grow at a relatively faster pace. This can be attributed to the ability of small molecules to easily pass through the cell membranes, enabling selective targeting of biomarkers expressed on the tumor cells.

Kinase Inhibitor Segment is Likely to Dominate the Oncology Precision Medicine Market During the Forecast Period

Based on the drug class, the market is segmented into kinase inhibitors, enzyme inhibitors, immune checkpoint inhibitors and others. It is worth highlighting that, at present, kinase inhibitors hold a larger share of the oncology precision medicine market. This trend is likely to remain the same in the coming decade.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, and Latin America. The majority of the share is expected to be captured by drug developers based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR. This can be primarily attributed to the low cost investment for conducting clinical trials in Asian countries.

Example Players in the Oncology Precision Medicine Market

AbbVie
Anticancer Bioscience
Astellas Pharma
AstraZeneca
Bayer
Blueprint Medicines
Bristol Myers Squibb
Eli Lilly
Erasca
Genentech
GlaxoSmithKline
Hutchmed
IDEAYA Biosciences
Jiangsu Hengrui Pharmaceuticals
Johnson & Johnson Innovative Medicine
Merck
Novartis
Pfizer
Repare Therapeutics
Roche
Seagen
SpringWorks Therapeutics
Takeda Pharmaceutical
VERAXA Biotech GmbH
VRise Therapeutics

ONCOLOGY PRECISION MEDICINE MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the oncology precision medicine market, focusing on key market segments, including [A] type of cancer targeted, [B] route of administration, [C] type of molecule, [D] drug class, [E] key geographical regions and [F] leading drug developers.
Market Landscape: A comprehensive evaluation of commercialized and clinical stage oncology precision medicines, considering various parameters, such as [A] stage of development, [B] approval body, [C] approval region, [D] drug designation, [E] type of molecule, [F] drug class, [G] route of administration, [H] dosage regimen, [I] patient population and [K] type of cancer targeted. Furthermore, the chapter includes a detailed analysis of the current landscape of discovery and preclinical stage oncology precision medicines, based on several relevant parameters, such as [L] stage of development, [M] type of molecule, [N] drug class and [O] type of cancer targeted. Additionally, the chapter features information on various drug developers, along with analysis based on multiple parameters, such as [P] year of establishment, [Q] company size and [R] location of headquarters.
Company Profiles: In-depth profiles of key industry players engaged in oncology precision medicine market, focusing on [A] company overviews, [B] financial information (if available), [C] oncology precision medicine portfolio, [D] recent developments and [E] an informed future outlook.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering clinical trial agreements, commercialization agreements, drug development agreements, drug development and commercialization agreements, drug distribution agreements, drug licensing agreements, manufacturing agreements, mergers / acquisitions, process development and manufacturing agreements, research agreements, research and development agreements, service agreements, technology utilization agreements and others.
Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies related to oncology precision medicine based on several parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] target patient population, [F] patient gender, [G] type of cancer targeted, [H] type of sponsor / collaborator, [I] study design, [J] most active sponsor / collaborator (leading industry and non-industry players based on the number of clinical trials sponsored), [K] emerging focus areas and [L] geography.
Case Study: A general discussion on the precision oncology assay kit developers, providing detailed analysis on various parameters such as [A] stage of development, [B] regulatory certification / compliance, [C] regional availability, [D] type of test, [E] type of sample, [F] principle of biomarker detection, [G] turnaround time, [H] type of cancer targeted and [I] end-user. Further, the chapter features information on various assay kit developers, along with analysis based on multiple parameters, such as [J] year of establishment, [K] company size and [L] location of headquarters.
Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the factors that are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Precision Medicine
- 5.2.1. Evolution of Precision Medicine
5.3. Oncology Precision Medicine
- 5.3.1. Oncology Precision Medicine over Traditional Cancer Medicine
- 5.3.2. Steps Involved in Developing Oncology Precision Medicine
- 5.3.3. Advantages Associated with Oncology Precision Medicine
  - 5.3.3.1. Benefits to the Patients
  - 5.3.3.2. Benefits to the Healthcare Providers
  - 5.3.3.3. Benefits to the Cancer Researchers
- 5.3.4. Challenges Associated with Oncology Precision Medicines
- 5.3.5. Future Perspectives

6. ONCOLOGY PRECISION MEDICINE: MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Oncology Precision Medicine: Commercialized and Clinical Stage Drugs Market Landscape
- 6.2.1. Analysis by Stage of Development
- 6.2.2. Analysis by Approval Body
- 6.2.3. Analysis by Approval Region
- 6.2.4. Analysis by Drug Designation
- 6.2.5. Analysis by Type of Molecule
- 6.2.6. Analysis by Drug Class
- 6.2.7. Analysis by Route of Administration
- 6.2.8. Analysis by Dosage Regimen
- 6.2.9. Analysis by Patient Population
- 6.2.10. Analysis by Type of Cancer Targeted
- 6.2.11. Analysis by Stage of Development and Type of Cancer Targeted
6.3. Oncology Precision Medicine: Preclinical and Discovery Stage Drugs Market Landscape
- 6.3.1. Analysis by Stage of Development
- 6.3.2. Analysis by Type of Molecule
- 6.3.3. Analysis by Drug Class
- 6.3.4. Analysis by Type of Cancer Targeted
6.4. Oncology Precision Medicine: Developer Landscape
- 6.4.1. Analysis by Year of Establishment
- 6.4.2. Analysis by Company Size
- 6.4.3. Analysis by Location of Headquarters (Region)
- 6.4.4. Analysis by Location of Headquarters (Country)
- 6.4.5. Analysis by Company Size and Location of Headquarters (Region)
- 6.4.6. Most Active Players: Analysis by Number of Oncology Precision Medicines

7. DETAILED COMPANY PROFILES

7.1. Chapter Overview
7.2. AstraZeneca
- 7.2.1. Company Overview
- 7.2.2. Financial Information
- 7.2.3. Oncology Precision Medicine Portfolio
- 7.2.4. Recent Developments and Future Outlook
7.3. Genentech
- 7.3.1. Company Overview
- 7.3.2. Financial Information
- 7.3.3. Oncology Precision Medicine Portfolio
- 7.3.4. Recent Developments and Future Outlook
7.4. Jiangsu Hengrui Pharmaceuticals
- 7.4.1. Company Overview
- 7.4.2. Oncology Precision Medicine Portfolio
- 7.4.3. Recent Developments and Future Outlook
7.5. Johnson & Johnson Innovative Medicine
- 7.5.1. Company Overview
- 7.5.2. Financial Information
- 7.5.3. Oncology Precision Medicine Portfolio
- 7.5.4. Recent Developments and Future Outlook
7.6. Novartis
- 7.6.1. Company Overview
- 7.6.2. Financial Information
- 7.6.3. Oncology Precision Medicine Portfolio
- 7.6.4. Recent Developments and Future Outlook
7.7. Pfizer
- 7.7.1. Company Overview
- 7.7.2. Financial Information
- 7.7.3. Oncology Precision Medicine Portfolio
- 7.7.4. Recent Developments and Future Outlook
7.8. SpringWorks Therapeutics
- 7.8.1. Company Overview
- 7.8.2. Oncology Precision Medicine Portfolio
- 7.8.3. Recent Developments and Future Outlook

8. SHORT COMPANY PROFILES

8.1. Chapter Overview
8.2. AbbVie
8.3. Anticancer Bioscience
8.4. Astellas Pharma
8.5. Bayer
8.6. Blueprint Medicines
8.7. Bristol Myers Squibb
8.8. Eli Lilly
8.9. Erasca
8.10. GlaxoSmithKline
8.11. Hutchmed
8.12. IDEAYA Biosciences
8.13. Merck
8.14. Repare Therapeutics
8.15. Roche
8.16. Seagen
8.17. Takeda Pharmaceutical
8.18. VERAXA Biotech
8.19. VRise Therapeutics

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Oncology Precision Medicine: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Analysis by Drug Involved
- 9.3.6. Analysis by Type of Cancer Targeted
- 9.3.7. Most Active Players: Analysis by Number of Partnerships
- 9.3.8. Analysis by Geography
  - 9.3.8.1. Local and International Agreements
  - 9.3.8.2. Intracontinental and Intercontinental Agreements

10. CLINICAL TRIAL ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Oncology Precision Medicine: Clinical Trial Analysis
- 10.3.1. Analysis by Trial Registration Year
- 10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
- 10.3.3. Analysis by Trial Phase
- 10.3.4. Analysis of Number of Patients Enrolled by Trial Phase
- 10.3.5. Analysis by Trial Registration Year and Trial Phase
- 10.3.6. Analysis by Trial Status
- 10.3.7. Analysis by Trial Registration Year and Trial Status
- 10.3.8. Analysis by Target Patient Population
- 10.3.9. Analysis by Patient Gender
- 10.3.10. Analysis by Type of Cancer Targeted
- 10.3.11. Analysis by Type of Sponsor / Collaborator
- 10.3.12. Analysis by Study Design
  - 10.3.12.1. Analysis by Type of Trial Masking
  - 10.3.12.2. Analysis by Type of Intervention Model
  - 10.3.12.3. Analysis by Type of Intervention
  - 10.3.12.4. Analysis by Trial Purpose
- 10.3.13. Most Active Sponsors / Collaborators: Analysis by Number of Clinical Trials
  - 10.3.13.1. Analysis by Leading Industry Players
  - 10.3.13.2. Analysis by Leading Non-Industry Players
- 10.3.14. Word Cloud Analysis: Emerging Focus Areas
- 10.3.15. Analysis by Geography
  - 10.3.15.1. Analysis of Clinical Trials by Geography
  - 10.3.15.2. Analysis of Clinical Trials by Geography and Trial Status
  - 10.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status

11. CASE STUDY: ONCOLOGY PRECISION MEDICINE ASSAY KITS

11.1. Chapter Overview
11.2. Oncology Precision Medicine: Assay Kits
- 11.2.1. Analysis by Stage of Development
- 11.2.2. Analysis by Regulatory Certification / Compliance
- 11.2.3. Analysis by Regional Availability
- 11.2.4. Analysis by Type of Test
- 11.2.5. Analysis by Type of Sample Used
- 11.2.6. Analysis by Principle of Biomarker Detection
- 11.2.7. Analysis by Turnaround Time
- 11.2.8. Analysis by Type of Cancer Targeted
- 11.2.9. Analysis by Turnaround Time and Type of Cancer Targeted
- 11.2.10. Analysis by End-user
- 11.2.11. Analysis by Regional Availability and End-user
- 11.2.12. Analysis by Type of Cancer Targeted and End-user
11.3. Oncology Precision Medicine Assay Kits: Developer Landscape
- 11.3.1. Analysis by Year of Establishment
- 11.3.2. Analysis by Company Size
- 11.3.3. Analysis by Location of Headquarters (Region)
- 11.3.4. Analysis by Location of Headquarters (Country)
- 11.3.5. Analysis by Company Size and Location of Headquarters (Region)
- 11.3.6. Analysis by Business Model
- 11.3.7. Most Active Players: Analysis by Number of Oncology Precision Medicine Assay Kits

12. CASE STUDY: TECHNOLOGIES USED IN PRECISION MEDICINE

12.1. Chapter Overview
12.2. Technologies Used in Precision Medicine
- 12.2.1. Next Generation Sequencing in Precision Medicine
- 12.2.2. Nanotechnology in Precision Medicine
- 12.2.3. Molecular Imaging Technologies in Precision Medicine
- 12.2.4. Omics Technologies in Precision Medicine
- 12.2.5. Artificial Intelligence (AI) in Precision Medicine
12.3. Conclusion

13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion

14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET

14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Global Oncology Precision Medicine Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
14.4. Scenario Analysis
- 14.4.1. Conservative Scenario
- 14.4.2. Optimistic Scenario
14.5. Key Market Segmentations

15. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF CANCER TARGETED

15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
- 15.3.1. Bladder Cancer: Forecasted Estimates (till 2035)
- 15.3.2. Blood / Hematologic Cancer: Forecasted Estimates (till 2035)
- 15.3.3. Breast Cancer: Forecasted Estimates (till 2035)
- 15.3.4. Cervical Cancer: Forecasted Estimates (till 2035)
- 15.3.5. Gastrointestinal Cancer: Forecasted Estimates (till 2035)
- 15.3.6. Head and Neck Squamous Cell Cancer: Forecasted Estimates (till 2035)
- 15.3.7. Lung Cancer: Forecasted Estimates (till 2035)
- 15.3.8. Skin Cancer: Forecasted Estimates (till 2035)
- 15.3.9. Other Cancers: Forecasted Estimates (till 2035)
15.4. Data Triangulation and Validation

16. ONCOLOGY PRECISION MEDICINE MARKET, BY ROUTE OF ADMINISTRATION

16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
- 16.3.1. Oral: Forecasted Estimates (till 2035)
- 16.3.2. Intravenous: Forecasted Estimates (till 2035)
- 16.3.3. Others: Forecasted Estimates (till 2035)
16.4. Data Triangulation and Validation

17. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF MOLECULE

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
- 17.3.1. Small Molecules: Forecasted Estimates (till 2035)
- 17.3.2. Biologics: Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation

18. ONCOLOGY PRECISION MEDICINE MARKET, BY DRUG CLASS

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
- 18.3.1. Kinase Inhibitors: Forecasted Estimates (till 2035)
- 18.3.2. Enzyme Inhibitors: Forecasted Estimates (till 2035)
- 18.3.3. Immune Checkpoint Inhibitors: Forecasted Estimates (till 2035)
- 18.3.4. Others: Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation

19. ONCOLOGY PRECISION MEDICINE MARKET, BY KEY GEOGRAPHICAL REGIONS

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
- 19.3.1. North America: Forecasted Estimates (till 2035)
  - 19.3.1.1. US: Forecasted Estimates (till 2035)
  - 19.3.1.2. Canada: Forecasted Estimates (till 2035)
- 19.3.2. Europe: Forecasted Estimates (till 2035)
  - 19.3.2.1. France: Forecasted Estimates (till 2035)
  - 19.3.2.2. Germany: Forecasted Estimates (till 2035)
  - 19.3.2.3. Italy: Forecasted Estimates (till 2035)
  - 19.3.2.4. Spain: Forecasted Estimates (till 2035)
  - 19.3.2.5. UK: Forecasted Estimates (till 2035)
- 19.3.3. Asia: Forecasted Estimates (till 2035)
  - 19.3.3.1. China: Forecasted Estimates (till 2035)
  - 19.3.3.2. Japan: Forecasted Estimates (till 2035)
  - 19.3.3.3. Korea: Forecasted Estimates (till 2035)
  - 19.3.3.4. India: Forecasted Estimates (till 2035)
- 19.3.4. Middle East and North Africa: Forecasted Estimates (till 2035)
  - 19.3.4.1. UAE: Forecasted Estimates (till 2035)
  - 19.3.4.2. Israel: Forecasted Estimates (till 2035)
  - 19.3.4.3. Qatar: Forecasted Estimates (till 2035)
  - 19.3.4.4. Rest of Middle east and North Africa: Forecasted Estimates (till 2035)
- 19.3.5. Latin America: Forecasted Estimates (till 2035)
  - 19.3.5.1. Brazil: Forecasted Estimates (till 2035)
  - 19.3.5.2. Argentina: Forecasted Estimates (till 2035)
  - 19.3.5.3. Chile: Forecasted Estimates (till 2035)
  - 19.3.5.4. Rest of Latin America: Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation

20. ONCOLOGY PRECISION MEDICINE MARKET, SALES FORECAST OF DRUGS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Blockbuster Commercialzied Oncology Precision Medicine Market: Sales Forecast
- 20.3.1. ADCETRIS(R) Sales Forecast
- 20.3.2. Alecensa(R) Sales Forecast
- 20.3.3. ALUNBRIG(R) Sales Forecast
- 20.3.4. Avastin(R) Sales Forecast
- 20.3.5. Ayvakit(R) Sales Forecast
- 20.3.6. Braftovi(R)+ Mektovi(R) Sales Forecast
- 20.3.7. BRUKINSA(R) Sales Forecast
- 20.3.8. CALQUENCE(R) Sales Forecast
- 20.3.9. DARZALEX(R) Sales Forecast
- 20.3.10. Elunate(R) Sales Forecast
- 20.3.11. Empliciti(R) Sales Forecast
- 20.3.12. Enhertu(R) Sales Forecast
- 20.3.13. IBRANCE(R) Sales Forecast
- 20.3.14. ICLUSIG(R) Sales Forecast
- 20.3.15. IMBRUVICA(R) Sales Forecast
- 20.3.16. IMFINZI(R) Sales Forecast
- 20.3.17. INLYTA(R) Sales Forecast
- 20.3.18. Keytruda(R) Sales Forecast
- 20.3.19. Kadcyla(R) Sales Forecast
- 20.3.20. LENVIMA(R) / KISPLYX(R) Sales Forecast
- 20.3.21. Lumakras(R) / Lumykras(R) Sales Forecast
- 20.3.22. Mekinist(R) Sales Forecast
- 20.3.23. NERLYNX(R) Sales Forecast
- 20.3.24. NINLARO(R) Sales Forecast
- 20.3.25. Opdivo(R) Sales Forecast
- 20.3.26. Padcev(R) Sales Forecast
- 20.3.27. Piqray(R) Sales Forecast
- 20.3.28. Sprycel(R) Sales Forecast
- 20.3.29. Tabrecta(R) Sales Forecast
- 20.3.30. Tagrisso(R) Sales Forecast
- 20.3.31. Tasigna(R) Sales Forecast
- 20.3.32. Tecentriq(R) Sales Forecast
- 20.3.33. VENCLEXTA(R) Sales Forecast
- 20.3.34. Verzenio(R) / Verzenios Sales Forecast
- 20.3.35. Xospata(R) Sales Forecast
- 20.3.36. Xtandi(R) Sales Forecast
- 20.3.37. ZEJULA(R) Sales Forecast
20.4. NDA-filed Oncology Precision Medicine Market: Sales Forecast
- 20.4.1. Apatinib / Rivoceranib Sales Forecast
- 20.4.2. Elunate(R) Sales Forecast
20.5. Phase III Oncology Precision Medicine Market: Sales Forecast
- 20.5.1. Darovasertib / IDE196 Sales Forecast
  - 20.5.1.1. Darovasertib / IDE196 Regional Sales Forecast
- 20.5.2. Elenestinib / BLU-263 Sales Forecast
  - 20.5.2.1. Elenestinib / BLU-263 Regional Sales Forecast
- 20.5.3. Elunate(R) Sales Forecast
  - 20.5.3.1. Elunate(R) Sales Forecast by Type of Cancer Targeted
  - 20.5.3.2. Elunate(R) Regional Sales Forecast
- 20.5.4. ORPATHYS(R) Sales Forecast
  - 20.5.4.1. ORPATHYS(R) Regional Sales Forecast
- 20.5.5. Pyrotinib Sales Forecast
  - 20.5.5.1. Pyrotinib Sales Forecast by Type of Cancer Targeted
  - 20.5.5.2. Pyrotinib Regional Sales Forecast
- 20.5.6. SYD985 / (Vic-) trastuzumab duocarmazine) Sales Forecast
  - 20.5.6.1. SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast
- 20.5.7. ZOLINZA(R) Sales Forecast
  - 20.5.7.1. ZOLINZA(R) Regional Sales Forecast

21. ONCOLOGY PRECISION MEDICINE MARKET, BY LEADING DRUG DEVELOPERS

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Oncology Precision Medicine Market: Distribution by Leading Drug Developers
21.4. Data Triangulation and Validattion

22. CONCLUSION

23. EXECUTIVE INSIGHTS

23.1. Chapter Overview
23.2. Company A
- 23.2.1. Company Snapshot
- 23.2.2. Interview Transcript
23.3. Company B
- 23.3.1. Company Snapshot
- 23.3.2. Interview Transcript

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

簡介目錄圖表

List of Tables

Table 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Developer, Brand, Stage of Development, Approval Body and Approval Region
Table 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Drug Designation
Table 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Molecule, Drug Class, Route of Administration, Dosage Regimen and Patient Population
Table 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Cancer Targeted
Table 6.5 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Developer and Stage of Development
Table 6.6 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Molecule and Drug Class
Table 6.7 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Cancer Targeted
Table 6.8 Oncology Precision Medicine: List of Developers
Table 7.1 Oncology Precision Medicine: List of Companies Profiled
Table 7.2 AstraZeneca: Company Snapshot
Table 7.3 AstraZeneca: Oncology Precision Medicine Portfolio
Table 7.4 AstraZeneca: Recent Developments and Future Outlook
Table 7.5 Genentech: Company Snapshot
Table 7.6 Genentech: Oncology Precision Medicine Portfolio
Table 7.7 Jiangsu Hengrui Pharmaceuticals: Company Snapshot
Table 7.8 Jiangsu Hengrui Pharmaceuticals: Oncology Precision Medicine Portfolio
Table 7.9 Johnson & Johnson Innovative Medicine: Company Snapshot
Table 7.10 Johnson & Johnson Innovative Medicine: Oncology Precision Medicine Portfolio
Table 7.11 Johnson & Johnson Innovative Medicine: Recent Developments and Future Outlook
Table 7.12 Novartis: Company Snapshot
Table 7.13 Novartis: Oncology Precision Medicine Portfolio
Table 7.14 Novartis: Recent Developments and Future Outlook
Table 7.15 Pfizer: Company Snapshot
Table 7.16 Pfizer: Oncology Precision Medicine Portfolio
Table 7.17 Pfizer: Recent Developments and Future Outlook
Table 7.18 SpringWorks Therapeutics: Company Snapshot
Table 7.19 SpringWorks Therapeutics: Oncology Precision Medicine Portfolio
Table 7.20 SpringWorks Therapeutics: Recent Developments and Future Outlook
Table 8.1 Oncology Precision Medicine: List of Companies Profiled
Table 8.2 Company Profile: AbbVie
Table 8.3 Company Profile: Anticancer Biosciences
Table 8.4 Company Profile: Astellas Pharma
Table 8.5 Company Profile: Bayer
Table 8.6 Company Profile: Blueprint Medicines
Table 8.7 Company Profile: Bristol Myers Squibb
Table 8.8 Company Profile: Eli Lilly
Table 8.9 Company Profile: Erasca
Table 8.10 Company Profile: GlaxoSmithKline
Table 8.11 Company Profile: Hutchmed
Table 8.12 Company Profile: IDEAYA Biosciences
Table 8.13 Company Profile: Merck
Table 8.14 Company Profile: Repare Therapeutics
Table 8.15 Company Profile: Roche
Table 8.16 Company Profile: Seagen
Table 8.17 Company Profile: Takeda Pharmaceutical
Table 8.18 Company Profile: VERAXA Biotech GmbH
Table 8.19 Company Profile: VRise Therapeutics
Table 9.1 Oncology Precision Medicine: List of Partnerships and Collaborations, since 2018
Table 9.2 Partnerships and Collaborations: Information on Drug Involved and Type of Cancer Targeted
Table 9.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 11.1 Oncology Precision Medicine Assay Kits: Information on Developer, Stage of Development, Regulatory Certification / Compliance and Regional Availability
Table 11.2 Oncology Precision Medicine Assay Kits: Information on Type of Test, Type of Sample, Principle of Biomarker Detection and Turn-around Time
Table 11.3 Oncology Precision Medicine Assay Kits: Information on Type of Cancer Targeted
Table 11.4 Oncology Precision Medicine Assay Kits: Information on End-user
Table 11.5 List of Oncology Precision Medicine Assay Kit Developers
Table 21.1 List of Leading Oncology Precision Medicine Developers
Table 23.1 Allarity Therapeutics: Company Snapshot
Table 23.2 Elephas: Company Snapshot
Table 24.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development
Table 24.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body
Table 24.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region
Table 24.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation
Table 24.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule
Table 24.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class
Table 24.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration
Table 24.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen
Table 24.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population
Table 24.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Table 24.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted
Table 24.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development
Table 24.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule
Table 24.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class
Table 24.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Table 24.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment
Table 24.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size
Table 24.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)
Table 24.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)
Table 24.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)
Table 24.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines
Table 24.22 AstraZeneca: Annual Revenues, FY 2018 Onwards (USD Billion)
Table 24.23 Roche (Parent Company of Genentech): Annual Revenues, FY 2018 Onwards (USD Billion)
Table 24.24 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018 Onwards (USD Billion)
Table 24.25 Novartis: Annual Revenues, FY 2018 Onwards (USD Billion)
Table 24.26 Pfizer: Annual Revenues, FY 2018 Onwards (USD Billion)
Table 24.27 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2018
Table 24.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership, since 2018
Table 24.30 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.31 Partnerships and Collaborations: Distribution by Drug Involved
Table 24.32 Partnerships and Collaborations: Distribution by Type of Cancer Targeted
Table 24.33 Most Active Players: Distribution by Number of Partnerships
Table 24.34 Partnership and Collaborations: Local and International Agreements
Table 24.35 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 24.36 Clinical Trial Analysis: Cumulative Year-wise Trend, since 2018
Table 24.37 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, since 2018
Table 24.38 Clinical Trial Analysis: Distribution by Trial Phase
Table 24.39 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Table 24.40 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, since 2018
Table 24.41 Clinical Trial Analysis: Distribution by Trial Status
Table 24.42 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, since 2018
Table 24.43 Clinical Trial Analysis: Distribution by Target Patient Population
Table 24.44 Clinical Trial Analysis: Distribution by Patient Gender
Table 24.45 Clinical Trial Analysis: Distribution by Type of Cancer Targeted
Table 24.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 24.47 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 24.48 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 24.49 Clinical Trial Analysis: Distribution by Type of Intervention
Table 24.50 Clinical Trial Analysis: Distribution by Trial Purpose
Table 24.51 Leading Industry Players: Distribution by Number of Clinical Trials
Table 24.52 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Table 24.53 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 24.54 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 24.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 24.56 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
Table 24.57 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
Table 24.58 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
Table 24.59 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
Table 24.60 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
Table 24.61 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
Table 24.62 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
Table 24.63 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
Table 24.64 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
Table 24.65 Oncology Precision Medicine Assay Kits: Distribution by End-user
Table 24.66 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
Table 24.67 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
Table 24.68 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
Table 24.69 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
Table 24.70 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
Table 24.71 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)
Table 24.72 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.73 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model
Table 24.74 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed
Table 24.75 Global Oncology Precision Medicine Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 24.76 Global Oncology Precision Medicine Market, till 2035: Conservative Scenario (USD Billion)
Table 24.77 Global Oncology Precision Medicine Market, till 2035: Optimistic Scenario (USD Billion)
Table 24.78 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
Table 24.79 Oncology Precision Medicine Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.80 Oncology Precision Medicine Market for Blood / Hematologic Cancer, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.81 Oncology Precision Medicine Market for Breast Cancer, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.82 Oncology Precision Medicine Market for Cervical Cancer, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.83 Oncology Precision Medicine Market for Gastrointestinal Cancer, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.84 Oncology Precision Medicine Market for Head and Neck Squamous Cell Cancer, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.85 Oncology Precision Medicine Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.86 Oncology Precision Medicine Market for Skin Cancer, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.87 Oncology Precision Medicine Market for Other Cancers, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.88 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
Table 24.89 Oncology Precision Medicine Market for Oral, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.90 Oncology Precision Medicine Market for Intravenous, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.91 Oncology Precision Medicine Market for Others, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.92 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
Table 24.93 Oncology Precision Medicine Market for Small Molecules, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.94 Oncology Precision Medicine Market for Biologics, Conservative, Base and Optimistic Scenarios, till 2035, (USD Billion)
Table 24.95 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
Table 24.96 Oncology Precision Medicine Market for Kinase Inhibitors, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.97 Oncology Precision Medicine Market for Enzyme Inhibitors, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.98 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.99 Oncology Precision Medicine Market for Others, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.100 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
Table 24.101 Oncology Precision Medicine Market in North America, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.102 Oncology Precision Medicine Market in the US, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.103 Oncology Precision Medicine Market in Canada, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.104 Oncology Precision Medicine Market in Europe, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.105 Oncology Precision Medicine Market in France, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.106 Oncology Precision Medicine Market in Germany, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.107 Oncology Precision Medicine Market in Italy, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.108 Oncology Precision Medicine Market in Spain, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.109 Oncology Precision Medicine Market in UK, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.110 Oncology Precision Medicine Market in Asia, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.111 Oncology Precision Medicine Market in China, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.112 Oncology Precision Medicine Market in Japan, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.113 Oncology Precision Medicine Market in Korea, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.114 Oncology Precision Medicine Market in India, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.115 Oncology Precision Medicine Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.116 Oncology Precision Medicine Market in UAE, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.117 Oncology Precision Medicine Market in Israel, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.118 Oncology Precision Medicine Market in Qatar, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.119 Oncology Precision Medicine Market in Rest of Middle East and North Africa, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.120 Oncology Precision Medicine Market in Latin America, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.121 Oncology Precision Medicine Market in Brazil, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.122 Oncology Precision Medicine Market in Argentina, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.123 Oncology Precision Medicine Market in Chile, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.124 Oncology Precision Medicine Market in Rest of Latin America, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.125 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRIS(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.126 Blockbuster Commercialized Oncology Precision Medicine Market: Alecensa(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.127 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIG(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.128 Blockbuster Commercialized Oncology Precision Medicine Market: Avastin(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.129 Blockbuster Commercialized Oncology Precision Medicine Market: Ayvakit(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.130 Blockbuster Commercialized Oncology Precision Medicine Market: Braftovi(R)+ Mektovi(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.131 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSA(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.132 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCE(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.133 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEX(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.134 Blockbuster Commercialized Oncology Precision Medicine Market: Elunate(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.135 Blockbuster Commercialized Oncology Precision Medicine Market: Empliciti(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.136 Blockbuster Commercialized Oncology Precision Medicine Market: Enhertu(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.137 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCE(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.138 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIG(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.139 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICA(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.140 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZI(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.141 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTA(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.142 Blockbuster Commercialized Oncology Precision Medicine Market: Keytruda(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.143 Blockbuster Commercialized Oncology Precision Medicine Market: Kadcyla(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.144 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMA(R) / KISPLYX(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.145 Blockbuster Commercialized Oncology Precision Medicine Market: Lumakras(R) / Lumykras(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.146 Blockbuster Commercialized Oncology Precision Medicine Market: Mekinist(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.147 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNX(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.148 Blockbuster Commercialized Oncology Precision Medicine Market: NINLARO(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.149 Blockbuster Commercialized Oncology Precision Medicine Market: Opdivo(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.150 Blockbuster Commercialized Oncology Precision Medicine Market: Padcev(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.151 Blockbuster Commercialized Oncology Precision Medicine Market: Piqray(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.152 Blockbuster Commercialized Oncology Precision Medicine Market: Sprycel(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.153 Blockbuster Commercialized Oncology Precision Medicine Market: Tabrecta(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.154 Blockbuster Commercialized Oncology Precision Medicine Market: Tagrisso(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.155 Blockbuster Commercialized Oncology Precision Medicine Market: Tasigna(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.156 Blockbuster Commercialized Oncology Precision Medicine Market: Tecentriq(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.157 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTA(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.158 Blockbuster Commercialized Oncology Precision Medicine Market: Verzenio(R) / Verzenios Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.159 Blockbuster Commercialized Oncology Precision Medicine Market: Xospata(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.160 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDI(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.161 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULA(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.162 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.163 NDA-filed Oncology Precision Medicine Market: Elunate(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.164 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.165 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.166 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.167 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.168 Phase III Oncology Precision Medicine Market: Elunate(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.169 Phase III Oncology Precision Medicine Market: Elunate(R) Sales Forecast by Type of Cancer Targeted, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.170 Phase III Oncology Precision Medicine Market: Elunate(R) Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.171 Phase III Oncology Precision Medicine Market: ORPATHYS(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.172 Phase III Oncology Precision Medicine Market: ORPATHYS(R) Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.173 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.174 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.175 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.176 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.177 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.178 Phase III Oncology Precision Medicine Market: ZOLINZA(R) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.179 Phase III Oncology Precision Medicine Market: ZOLINZA(R) Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 24.180 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines (USD Billion)

List of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Evolution of Precision Medicine
Figure 5.2 Oncology Precision Medicine over Traditional Cancer Medicine
Figure 5.3 Steps Involved in Developing Oncology Precision Medicines
Figure 5.4 Challenges Associated with Oncology Precision Medicines
Figure 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development
Figure 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body
Figure 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region
Figure 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation
Figure 6.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule
Figure 6.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class
Figure 6.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration
Figure 6.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen
Figure 6.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population
Figure 6.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Figure 6.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted
Figure 6.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development
Figure 6.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule
Figure 6.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class
Figure 6.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Figure 6.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment
Figure 6.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size
Figure 6.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)
Figure 6.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)
Figure 6.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)
Figure 6.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines
Figure 7.1 AstraZeneca: Annual Revenues, FY 2018 Onwards (USD Billion)
Figure 7.2 Roche (Parent Company of Genentech): Annual Revenues, FY 2018 Onwards (USD Billion)
Figure 7.3 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018 Onwards (USD Billion)
Figure 7.4 Novartis: Annual Revenues, FY 2018 Onwards (USD Billion)
Figure 7.5 Pfizer: Annual Revenues, FY 2018 Onwards (USD Billion)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2018
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, since 2018
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Drug Involved
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Cancer Targeted
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnership and Collaborations: Local and International Agreements
Figure 9.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 10.1 Clinical Trial Analysis: Cumulative Year-wise Trend, since 2018
Figure 10.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, since 2018
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, since 2018
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, since 2018
Figure 10.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 10.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Cancer Targeted
Figure 10.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.12 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 10.13 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 10.14 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 10.15 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 10.16 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 10.17 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Figure 10.18 Word Cloud Analysis: Emerging Focus Areas
Figure 10.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 10.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 10.21 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 11.1 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
Figure 11.2 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
Figure 11.3 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
Figure 11.4 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
Figure 11.5 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
Figure 11.6 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
Figure 11.7 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
Figure 11.8 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
Figure 11.9 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
Figure 11.10 Oncology Precision Medicine Assay Kits: Distribution by End-user
Figure 11.11 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
Figure 11.12 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
Figure 11.13 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
Figure 11.14 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
Figure 11.15 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
Figure 11.16 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)
Figure 11.17 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 11.18 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model
Figure 11.19 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed
Figure 12.1 Applications of NGS in Oncology Precision Medicine
Figure 12.2 Applications of Nanotechnology in Oncology Precision Medicine
Figure 12.3 Applications of Molecular Imaging Technologies in Oncology Precision Medicine
Figure 12.4 Applications of Omics Technologies in Oncology Precision Medicine
Figure 12.5 Applications of AI in Oncology Precision Medicine
Figure 13.1 Oncology Precision Medicine: Market Drivers
Figure 13.2 Oncology Precision Medicine: Market Restraints
Figure 13.3 Oncology Precision Medicine: Market Opportunities
Figure 13.4 Oncology Precision Medicine: Market Challenges
Figure 14.1 Global Oncology Precision Medicine Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 14.2 Global Oncology Precision Medicine Market, till 2035: Conservative Scenario (USD Billion)
Figure 14.3 Global Oncology Precision Medicine Market, till 2035: Optimistic Scenario (USD Billion)
Figure 15.1 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
Figure 15.2 Oncology Precision Medicine Market for Bladder Cancer, till 2035 (USD Billion)
Figure 15.3 Oncology Precision Medicine Market for Blood / Hematologic Cancer, till 2035 (USD Billion)
Figure 15.4 Oncology Precision Medicine Market for Breast Cancer, till 2035 (USD Billion)
Figure 15.5 Oncology Precision Medicine Market for Cervical Cancer, till 2035 (USD Billion)
Figure 15.6 Oncology Precision Medicine Market for Gastrointestinal Cancer, till 2035 (USD Billion)
Figure 15.7 Oncology Precision Medicine Market for Head and Neck Squamous Cancer, till 2035 (USD Billion)
Figure 15.8 Oncology Precision Medicine Market for Lung Cancer, till 2035 (USD Billion)
Figure 15.9 Oncology Precision Medicine Market for Skin Cancer, till 2035 (USD Billion)
Figure 15.10 Oncology Precision Medicine Market for Other Cancers, till 2035 (USD Billion)
Figure 16.1 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
Figure 16.2 Oncology Precision Medicine Market for Oral, till 2035 (USD Billion)
Figure 16.3 Oncology Precision Medicine Market for Intravenous, till 2035 (USD Billion)
Figure 16.4 Oncology Precision Medicine Market for Others, till 2035 (USD Billion)
Figure 17.1 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
Figure 17.2 Oncology Precision Medicine Market for Small Molecules, till 2035 (USD Billion)
Figure 17.3 Oncology Precision Medicine Market for Biologics, till 2035, (USD Billion)
Figure 18.1 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
Figure 18.2 Oncology Precision Medicine Market for Kinase Inhibitors, till 2035 (USD Billion)
Figure 18.3 Oncology Precision Medicine Market for Enzyme Inhibitors, till 2035 (USD Billion)
Figure 18.4 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, till 2035 (USD Billion)
Figure 18.5 Oncology Precision Medicine Market for Others, till 2035 (USD Billion)
Figure 19.1 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
Figure 19.2 Oncology Precision Medicine Market in North America, till 2035 (USD Billion)
Figure 19.3 Oncology Precision Medicine Market in the US, till 2035 (USD Billion)
Figure 19.4 Oncology Precision Medicine Market in Canada, till 2035 (USD Billion)
Figure 19.5 Oncology Precision Medicine Market in Europe, till 2035 (USD Billion)
Figure 19.6 Oncology Precision Medicine Market in France, till 2035 (USD Billion)
Figure 19.7 Oncology Precision Medicine Market in Germany, till 2035 (USD Billion)
Figure 19.8 Oncology Precision Medicine Market in Italy, till 2035 (USD Billion)
Figure 19.9 Oncology Precision Medicine Market in Spain, till 2035 (USD Billion)
Figure 19.10 Oncology Precision Medicine Market in UK, till 2035 (USD Billion)
Figure 19.11 Oncology Precision Medicine Market in Asia, till 2035 (USD Billion)
Figure 19.12 Oncology Precision Medicine Market in China, till 2035 (USD Billion)
Figure 19.13 Oncology Precision Medicine Market in Japan, till 2035 (USD Billion)
Figure 19.14 Oncology Precision Medicine Market in Korea, till 2035 (USD Billion)
Figure 19.15 Oncology Precision Medicine Market in India, till 2035 (USD Billion)
Figure 19.16 Oncology Precision Medicine Market in Middle East and North Africa, till 2035 (USD Billion)
Figure 19.17 Oncology Precision Medicine Market in UAE, till 2035 (USD Billion)
Figure 19.18 Oncology Precision Medicine Market in Israel, till 2035 (USD Billion)
Figure 19.19 Oncology Precision Medicine Market in Qatar, till 2035 (USD Billion)
Figure 19.20 Oncology Precision Medicine Market in Rest of Middle East and North Africa, till 2035 (USD Billion)
Figure 19.21 Oncology Precision Medicine Market in Latin America, till 2035 (USD Billion)
Figure 19.22 Oncology Precision Medicine Market in Brazil, till 2035 (USD Billion)
Figure 19.18 Oncology Precision Medicine Market in Israel, till 2035 (USD Billion)
Figure 19.19 Oncology Precision Medicine Market in Chile, till 2035 (USD Billion)
Figure 19.20 Oncology Precision Medicine Market in Rest of Latin America, till 2035 (USD Billion)
Figure 20.1 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRIS(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.2 Blockbuster Commercialized Oncology Precision Medicine Market: Alecensa(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.3 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIG(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.4 Blockbuster Commercialized Oncology Precision Medicine Market: Avastin(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.5 Blockbuster Commercialized Oncology Precision Medicine Market: Ayvakit(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.6 Blockbuster Commercialized Oncology Precision Medicine Market: Braftovi(R)+ Mektovi(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.7 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSA(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.8 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCE(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.9 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEX(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.10 Blockbuster Commercialized Oncology Precision Medicine Market: Elunate(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.11 Blockbuster Commercialized Oncology Precision Medicine Market: Empliciti(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.12 Blockbuster Commercialized Oncology Precision Medicine Market: Enhertu(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.13 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCE(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.14 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIG(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.15 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICA(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.16 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZI(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.17 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTA(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.18 Blockbuster Commercialized Oncology Precision Medicine Market: Keytruda(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.19 Blockbuster Commercialized Oncology Precision Medicine Market: Kadcyla(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.20 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMA(R) / KISPLYX(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.21 Blockbuster Commercialized Oncology Precision Medicine Market: Lumakras(R) / Lumykras(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.22 Blockbuster Commercialized Oncology Precision Medicine Market: Mekinist(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.23 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNX(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.24 Blockbuster Commercialized Oncology Precision Medicine Market: NINLARO(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.25 Blockbuster Commercialized Oncology Precision Medicine Market: Opdivo(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.26 Blockbuster Commercialized Oncology Precision Medicine Market: Padcev(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.27 Blockbuster Commercialized Oncology Precision Medicine Market: Piqray(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.28 Blockbuster Commercialized Oncology Precision Medicine Market: Sprycel(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.29 Blockbuster Commercialized Oncology Precision Medicine Market: Tabrecta(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.30 Blockbuster Commercialized Oncology Precision Medicine Market: Tagrisso(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.31 Blockbuster Commercialized Oncology Precision Medicine Market: Tasigna(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.32 Blockbuster Commercialized Oncology Precision Medicine Market: Tecentriq(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.33 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTA(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.34 Blockbuster Commercialized Oncology Precision Medicine Market: Verzenio(R) / Verzenios Sales Forecast, till 2035 (USD Billion)
Figure 20.35 Blockbuster Commercialized Oncology Precision Medicine Market: Xospata(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.36 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDI(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.37 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULA(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.38 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, till 2035 (USD Billion)
Figure 20.39 NDA-filed Oncology Precision Medicine Market: Elunate(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.40 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, till 2035 (USD Billion)
Figure 20.41 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, till 2035 (USD Billion)
Figure 20.42 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, till 2035 (USD Billion)
Figure 20.43 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, till 2035 (USD Billion)
Figure 20.44 Phase III Oncology Precision Medicine Market: Elunate(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.45 Phase III Oncology Precision Medicine Market: Elunate(R) Sales Forecast by Type of Cancer Targeted, till 2035 (USD Billion)
Figure 20.46 Phase III Oncology Precision Medicine Market: Elunate(R) Regional Sales Forecast, till 2035 (USD Billion)
Figure 20.47 Phase III Oncology Precision Medicine Market: ORPATHYS(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.48 Phase III Oncology Precision Medicine Market: ORPATHYS(R) Regional Sales Forecast, till 2035 (USD Billion)
Figure 20.49 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, till 2035 (USD Billion)
Figure 20.50 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, till 2035 (USD Billion)
Figure 20.51 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, till 2035 (USD Billion)
Figure 20.52 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, till 2035 (USD Billion)
Figure 20.53 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Regional Sales Forecast, till 2035 (USD Billion)
Figure 20.54 Phase III Oncology Precision Medicine Market: ZOLINZA(R) Sales Forecast, till 2035 (USD Billion)
Figure 20.55 Phase III Oncology Precision Medicine Market: ZOLINZA(R) Regional Sales Forecast, till 2035 (USD Billion)
Figure 21.1 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines in the year 2022 (USD Billion))
Figure 22.1 Conclusion: Market Landscape
Figure 22.2 Conclusion: Partnerships and Collaborations
Figure 22.3 Conclusion: Clinical Trial Analysis
Figure 22.4 Conclusion: Case Study Oncology Precision Medicine Assay Kits
Figure 22.5 Conclusion: Market Forecast and Opportunity Analysis

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

精準診斷和醫療市場（按產品、技術、應用和最終用戶分類）- 2025-2030 年全球預測

全球精準醫療市場研究報告 - 產業分析、規模、佔有率、成長、趨勢和預測 2025 年至 2033 年

精準醫療市場 - 全球和區域分析：按生態系統、應用和區域 - 分析和預測（2024-2034 年）

全球精準醫療市場按應用、技術和地區分類

精準診斷和精準醫療市場按類型、適應症、產品、最終用戶和地區分類 - 預測至 2029 年

精密診斷市場規模、佔有率和成長分析（按產品類型、應用、最終用戶和地區）- 產業預測 2025-2032

精準醫療人工智慧的全球市場（~2030 年）：按應用、適應症、工具和最終用戶

精準醫療市場：依技術、應用程式、最終用戶、配置- 2025-2030 年全球預測

精準醫學(精密醫療)的共同研究及授權契約:2019年～2024年

腫瘤精準醫學市場：按類型、癌症類型、最終用途分類 - 2025-2030 年全球預測

▼

FAQ

腫瘤精密醫療市場:標的癌症類別，各給藥途徑，各分子類型，各類藥物，主要地區，新興國家市場，預測銷售額:2035年前的產業趨勢與全球預測

Oncology Precision Medicine Market by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers and Sales Forecast: Industry Trends and Global Forecasts, Till 2035

目錄

第1章 序文

第2章 調查手法

第3章 經濟以及其他的計劃特有的考慮事項

第4章 摘要整理

第5章 簡介

第6章 腫瘤精密醫療市:市場形勢

第7章 詳細的企業簡介

第8章 企業簡介

第9章 夥伴關係和合作

第10章 臨床試驗的分析

第11章 案例研究:腫瘤精密醫療市化驗套件

第12章 案例研究:精密醫療所使用的技術

第13章 對市場的影響分析:促進因素，阻礙因素，機會，課題

第14章 全球腫瘤學精密醫療市場

第15章 腫瘤精密醫療市市場，標的各癌症類型

第16章 腫瘤學精密醫療市場，各給藥途徑

第17章 腫瘤精密醫療市市場，各分子類型

第18章 腫瘤精密醫療市市場，各類藥物

第19章 腫瘤精密醫療市市場，各主要地區

第20章 腫瘤精密醫療市市場，醫藥品的銷售額預測

第21章 腫瘤精密醫療市市場，大醫藥品開發各企業

第22章 結論

第23章 執行洞察

第24章 附錄1:表格形式的資料

第25章 附錄2:企業·團體一覽

ONCOLOGY PRECISION MEDICINE MARKET: OVERVIEW

ONCOLOGY PRECISION MEDICINE MARKET: GROWTH AND TRENDS

ONCOLOGY PRECISION MEDICINE MARKET: KEY INSIGHTS

1. Presently over 125 drug developers, worldwide, are engaged in developing oncology precision medicines targeting various cancers; around 90% of these developers are headquartered in developed geographies.

2. Close to 55% of the oncology precision medicines have been commercialized; of these, close to 28% of the drugs target blood / hematologic type of cancer.

3. Around 85% oncology precision medicines in the preclinical and discovery stages of development are small molecules; of these, more than 30% of the drugs target kinase proteins.

4. In pursuit of expanding the oncology precision medicines pipeline, the partnership activity in this domain has witnessed substantial growth with an annualized rate of 16% over the last five years.

5. Close to one million patients have been recruited / enrolled in clinical trials, registered for the evaluation of oncology precision medicines, across different geographies.

6. Majority of the oncology precision medicine assay kits developers are headquartered in North America; further, more than 30% of the market is captured by large players established post-1990.

7. Around 80% of oncology precision medicine assay kits are diagnostic tests; over 55% of such kits can diagnose, prognose and predict various cancers and provide results within ten days.

8. Owing to the advantages offered by precision medicines in cancer, along with lesser side effects and high response rate, the preference for such drugs will steadily increase in foreseeable future.

9. With the rapid increase in the demand for gene-targeted drugs in the treatment of cancer, the opportunity for companies developing oncology precision medicines is poised to grow at a CAGR of close to 10%.

ONCOLOGY PRECISION MEDICINE MARKET: KEY SEGMENTS

Example Players in the Oncology Precision Medicine Market

ONCOLOGY PRECISION MEDICINE MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. ONCOLOGY PRECISION MEDICINE: MARKET LANDSCAPE

7. DETAILED COMPANY PROFILES

8. SHORT COMPANY PROFILES

9. PARTNERSHIPS AND COLLABORATIONS

10. CLINICAL TRIAL ANALYSIS

11. CASE STUDY: ONCOLOGY PRECISION MEDICINE ASSAY KITS

12. CASE STUDY: TECHNOLOGIES USED IN PRECISION MEDICINE

13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET

15. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF CANCER TARGETED

16. ONCOLOGY PRECISION MEDICINE MARKET, BY ROUTE OF ADMINISTRATION

17. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF MOLECULE

18. ONCOLOGY PRECISION MEDICINE MARKET, BY DRUG CLASS

19. ONCOLOGY PRECISION MEDICINE MARKET, BY KEY GEOGRAPHICAL REGIONS

20. ONCOLOGY PRECISION MEDICINE MARKET, SALES FORECAST OF DRUGS

21. ONCOLOGY PRECISION MEDICINE MARKET, BY LEADING DRUG DEVELOPERS

22. CONCLUSION

23. EXECUTIVE INSIGHTS

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures

第1章序文

第2章調查手法

第3章經濟以及其他的計劃特有的考慮事項

第4章摘要整理

第5章簡介

第6章腫瘤精密醫療市:市場形勢

第7章詳細的企業簡介

第8章企業簡介

第9章夥伴關係和合作

第10章臨床試驗的分析

第11章案例研究:腫瘤精密醫療市化驗套件

第12章案例研究:精密醫療所使用的技術

第13章對市場的影響分析:促進因素，阻礙因素，機會，課題

第14章全球腫瘤學精密醫療市場

第15章腫瘤精密醫療市市場，標的各癌症類型

第16章腫瘤學精密醫療市場，各給藥途徑

第17章腫瘤精密醫療市市場，各分子類型

第18章腫瘤精密醫療市市場，各類藥物

第19章腫瘤精密醫療市市場，各主要地區

第20章腫瘤精密醫療市市場，醫藥品的銷售額預測

第21章腫瘤精密醫療市市場，大醫藥品開發各企業

第22章結論

第23章執行洞察

第24章附錄1:表格形式的資料

第25章附錄2:企業·團體一覽